Edwards Lifesciences
1,220 hedge funds and large institutions have $34.2B invested in Edwards Lifesciences in 2023 Q3 according to their latest regulatory filings, with 109 funds opening new positions, 431 increasing their positions, 465 reducing their positions, and 152 closing their positions.
89% more call options, than puts
Call options by funds: $292M | Put options by funds: $155M
0.65% less ownership
Funds ownership: 81.65% → 81% (-0.65%)
7% less repeat investments, than reductions
Existing positions increased: 431 | Existing positions reduced: 465
5% less funds holding
Funds holding: 1,279 → 1,220 (-59)
27% less capital invested
Capital invested by funds: $46.7B → $34.2B (-$12.5B)
28% less first-time investments, than exits
New positions opened: 109 | Existing positions closed: 152
68% less funds holding in top 10
Funds holding in top 10: 19 → 6 (-13)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$260M |
| 2 |
WT
Wellcome Trust
London,
United Kingdom
|
+$230M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$198M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
+$179M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$112M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DZ Bank
Frankfurt Am Main,
Germany
|
-$566M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$223M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$200M |
| 4 |
Holocene Advisors
New York
|
-$152M |
| 5 |
Amundi
Paris,
France
|
-$120M |
EW Hedge Fund Activity: Q3 2023 in Review
1,220 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Edwards Lifesciences (EW) for Q3 2023, worth a combined $34.2B — down 27% from $46.7B a quarter earlier.
Sellers outnumbered buyers: 152 funds closed out of EW and 109 opened new positions — a net loss of 43 holders — while 465 trimmed existing stakes and 431 added.
The largest buyer was Capital International Investors, adding an estimated $260M. The largest seller was DZ Bank, cutting an estimated $566M.
- 1,220 institutional investors held Edwards Lifesciences (EW) as of Q3 2023, down from 1,279 in Q2 2023.
- Funds reported $34.2B of Edwards Lifesciences stock for Q3 2023, down 27% quarter-over-quarter.
- 109 funds opened new Edwards Lifesciences positions in Q3 2023 and 152 closed out, a net change of -43 holders.
- The largest Edwards Lifesciences buyer in Q3 2023 was Capital International Investors, an estimated $260M added.
- The largest Edwards Lifesciences seller in Q3 2023 was DZ Bank, an estimated $566M sold.
Based on aggregated 13F filings for Q3 2023.